Home Search

omalizumab - search results

If you're not happy with the results, please do another search
Xolair (omalizumab)

Study: Omalizumab (Xolair) May Help Treat Idiopathic Anaphylaxis

0
Small study finds drug may be effective in treating IA.
Omalizumab (Xolair)

Study: Treatment with Omalizumab Raises Tolerance in Patients with Severe Food Allergies

0
Patients reached full tolerance for 70.4% of the tested foods which were reintroduced to the patients’ diet without the need for OIT.
Immunology Biologics

Are Biologics the Future of Food Allergy Treatment? One Study Weighs Pros and Cons

UNC School of Medicine researchers delve into the perspectives of community and academic providers on the role of biologics and food allergy.

Bacon Safe for Alpha-Gal? Peanuts Safe for Peanut Allergy? GMOs in the News

2
Genetically modified alternatives are here, like it or not.
Viaskin Patch

Viaskin Patch Improves Treatment for Pediatric Milk Allergies

The patch releases small doses of a milk allergen protein through the skin without ingestion.
Xolair

FDA Approves Xolair for Children and Adults With One or More Food Allergies

A significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placebo.
Xolair

FDA Grants Xolair Priority Review for Children and Adults with Food Allergies

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure.
Xolair (omalizumab)

Biologic Showing Promise as Food Allergy Treatment in Ongoing Phase 3 Trial

0
Assessment for both single agent and add-on therapy.

United Biopharma’s Monoclonal Antibody Shows Promise in Neutralizing IgE

0
Shows promise for the treatment of chronic spontaneous urticaria, food allergies, asthma and eczema.
Halsey

Halsey Diagnosed with Mast Cell Activation Syndrome and a Host of Other Ailments. What...

0
Singer hospitalized for anaphylaxis numerous times.